GIM
AGRX

Granahan Investment Management’s Agile Therapeutics AGRX Stock Holding History

Granahan Investment Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-50
Closed -$566K – 228
2016
Q4 		$566K Sell
50
-136
-73% -$1.91M 0.02% 183
2016
Q3 		$2.6M Buy
186
+3
+2% +$42.8K 0.09% 172
2016
Q2 		$2.78M Sell
183
-5
-3% -$68.5K 0.1% 179
2016
Q1 		$2.34M Sell
188
-7
-4% -$90.4K 0.09% 190
2015
Q4 		$3.8M Buy
195
+98
+101% +$1.55M 0.13% 183
2015
Q3 		$1.31M Buy
97
+8
+9% +$142K 0.04% 238
2015
Q2 		$1.52M Sell
89
-2
-2% -$42.7K 0.04% 228
2015
Q1 		$1.69M Buy
+91
New +$1.59M 0.05% 218

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Granahan Investment Management's AGRX Position: Q1 2017 in Review

Granahan Investment Management sold out of Agile Therapeutics (AGRX) in Q1 2017, closing a stake of 50 shares — an estimated $566K sold.

Granahan Investment Management first reported a position in AGRX in Q1 2015 and held it in 8 quarters. The position peaked at $3.8M in Q4 2015. 48 funds tracked by Wall St. Rank hold AGRX as of Q1 2017.

  • Granahan Investment Management reported no remaining Agile Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Granahan Investment Management sold 50 Agile Therapeutics shares in Q1 2017, an estimated $566K.
  • Granahan Investment Management first reported a position in Agile Therapeutics in Q1 2015 and held it in 8 quarters.
  • Granahan Investment Management's Agile Therapeutics position peaked at $3.8M in Q4 2015.
  • 48 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2017.

Based on Granahan Investment Management's 13F filing for Q1 2017, filed 15 May 2017.